Related meetings

  • Sort:
  • Collapse:
  • Toggle dates:

Date & Time: July 31, 2018, 13:30-17:45

Place: Auditorium, Shonan iPark

Language: Japanese (Simultaneous translation between Jpn. and Eng.)

Admission: Free

Pre-Registration (Required):
(The online pre-registration will start on July 3.)

RNA binding proteins (RNABPs) are trans-acting effectors that generate transcriptomic complexity and safeguard cellular functions in the brain. Their mis-regulation and mutations are often implicated in multiple neurodegenerative and neurological disorders; for example, FUS and TARDBP participate in amyotrophic lateral sclerosis and frontotemporal lobar degeneration. Therefore, RNABPs research as a basis of potential therapeutic targets would widely impact on not only RNA biologists but also neurobiologists and clinician. We strongly believe that intensive studies would be necessary for dissecting out RNABPs functions to understand the underlying mechanism of RNABPs related diseases. Now this symposium will bring together experts from academia who are pioneering the RNA biology and Neuroscience for RNABPs research to discuss progress and potential impact of therapeutic target reaction.

Hideyuki Okano, Organizer


13:00-13:30 Site Open

13:30-13:35 Opening remarks Masato Yano

[Chair] Masato Yano

13:35-14:20 “RNABPs generate cell specific transcriptomics in central nervous system”
Masato Yano (Graduate School of Medical and Dental Sciences, Niigata Univ.)

14:20-15:05 “Molecular mechanism of nuclear body formation by architectural noncoding RNAs”
Tetsuro Hirose (Institute for Genetic Medicine, Hokkaido Univ.)

15:05-15:20 Break

[Chair] Hideyuki Okano

15:20-16:00 “Identification of network hub genes in FUS-dependent amyotrophic lateral sclerosis iPS cell models”
Masahiro Nogami (Takeda Pharmaceutical Company Ltd.)

16:00-16:45 “Involvement of RNA binding proteins in CNS disorders: Approaches using Stem Cell Technologies”
Hideyuki Okano (Graduate School of Medicine, Keio Univ.)

16:45-16:55 Break

16:55-17:40 “Investigation of abnormal RNA metabolism in ALS: from the viewpoint of treatment strategy”
Osamu Onodera (Brain Research Institute, Niigata Univ.)

17:40-17:45 Closing remarks Hideyuki Okano

17:45-18:45 Mixer

Contact: SIL Office (Takeda Pharmaceutical Company Ltd.)

2018-06-21 2018-07-31